enarhyazzh-CNzh-TWcsdanlettlfifrkadeelhihuisiditjakolvmsnofaplptruskslessvthtrukviyi

.........-----

translate arrow

BONN: August 08, 2017. Deutsche Post DHL (DPDHL) has reported a 4.7 percent increase in net profit to €1.18 billion on a 5.8 percent rise in revenue to €29.69 billion for the first half of 2017. Operating profit (EBIT) rose 6.2 percent to reach €1.76 billion for the H1 period.

Second quarter net profit rose 11.3 percent to €602 million as revenue rose 4.4 percent to €14.8 billion year-on-year. An EBIT of €841 million was the strongest in company history and the seventh consecutive all-time quarterly high.

DHL Supply Chain life sciencesChief executive officer Frank Appel said the group - which employs over 508,000 people in 220 countries - is forecasting an EBIT of €3.75 billion for 2017 and expects to maintain an average eight percent increase in annual operating profit to 2020. "All of our divisions, thanks to their focus on fast-growing markets such as global e- commerce, are optimally positioned for long-term growth," he declared.

Revenue from the company's Supply Chain division rose 1.5 percent in H1 to top €7.04 billion, driven in part by an 11 percent rise in its Asia Pacific Life Science and Healthcare business.

This week the division signed an MoU with Shanghai Pharma - which generated revenues of over US$18 billion last year - to provide enhanced quality control measures, streamlined distribution processes, and strengthened compliance with food and pharma regulations for the company.

"China's national market for drugs has grown rapidly in recent years to become the world's second-largest with an estimated growth to around US$167 billion by 2020,," said Shanghai Pharma president and executive director Cho Man. "Our partnership with DHL will help [us] become one of the world's foremost pharmaceutical manufacturers – supported by a global distribution network that combines world-class quality control with fast, seamless delivery."

DHL Supply Chain CEO for Greater China Yin Zou said the country's pharma industry has suffered historically from high levels of fragmentation amongst local customers and distributors which the government's new 'two-invoice' policy seeks to resolve: "In this regulatory climate, end-to-end supply chain management plays an increasingly crucial role in determining how effectively Chinese pharmaceuticals firms not only maintain sales locally, but gain traction abroad in a cost-effective and sustainable manner," he noted.

- powered by Quickchilli.com -